Pharmacology and Neuroscience of Antipsychotic Drugs

Schizophrenia: Third Edition

Volumn , Issue , 2011, Pages 483-514

  Waddington, John L ^a   O'Tuathaigh, Colm M P ^a   Remington, Gary J ^b  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

Adverse effects; Antipsychotics; Dopamine; Glutamate; PET; Psychological mechanisms; Serotonin; SPECT; Therapeutic efficacy

Indexed keywords

EID: 84861756386     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444327298.ch23     Document Type: Chapter

References (372)

1. Adams, C.E., Tharyan, P., Coutinho, E.S. et al. (2006) The schizophrenia drug-treatment paradox. British Journal of Psychiatry 189, 391-392.
2. Agid, O., Mamo, D., Ginovart, N. et al. (2007) Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response. Neuropsychopharmacology 32, 1209-1215.
3. Andrew, H.G.(1994) Clinical relationship of extrapyramidal symptoms and tardive dyskinesia. Canadian Journal of Psychiatry 39, S76-S80.
4. Akhondzadeh, S., Tabatabee, M.&Behnam B.(2007) Celecoxib as adjunctive therapy in schizophrenia. Schizophrenia Research 90, 179-185.
5. Albers, L.J., Musenga A.&Raggi, A.(2008) Iloperidone: a new benzisoxazole atypical antipsychotic drug. Expert Opinion on Investigational Drugs 17, 61-75.
6. Alphs, L.(2006) An industry perspective on the NIMH consensus statement on negative symptoms. Schizophrenia Bulletin 32 , 225-230.
7. Alphs, L., Panagides J.,&Lancaster, S.(2007) Asenapine in the treatment of negative symptoms of schizophrenia. Psychopharmacology Bulletin 40, 41-53.
8. Andree, B., Halldin, C., Vrijmoed-deVries, M. et al. (1997) Central 5-HT2A and D2 dopamine receptor occupancy after sublingual administration of ORG 5222 in healthy men. Psychopharmacology 131, 339-345.
9. Andrieux, A., Salin, P., Schweitzer, A. et al. (2006) Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia. Biological Psychiatry 60 , 1224-1230.
10. Arakawa, R., Ito, H., Takano, A. et al. (2008) Dose-fi nding study of paliperidone ER based on striatal and extrastriatal dopamine D(2) receptor occupancy in patients with schizophrenia. Psychopharmacology 197, 229-335.
11. Arnsten, A.F.T., Murphy, B.&Merchant, K.(2000) The selective dopamine D4 receptor antagonist, PNU-101387G, prevents stress-induced cognitive defi cits in monkeys. Neuropsychopharmacology 23, 405-410.
12. Arnt, J.&Skarsfeldt, T.(1998) Do novel antipsychotics have similar pharmacological characteristics? Neuropsychopharmacology 18, 63-101.
13. Arranz, M.J.&de Leon, J.(2007) Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Molecular Psychiatry 12, 707-747.
14. Assie, M.B., Ravailhe, V., Faucillon, V. et al. (2005) Contrasting contribution of 5-hydroxytryptamine1A receptor activation to neurochemical profi le of novel antipsychotics. Journal of Pharmacology and Experimental Therapeutics 315, 265-272.
15. Attarbaschi, T., Sacher, J., Geiss-Granadia, T. et al. (2007) Striatal D(2) receptor occupancy in bipolar patients treated with olanzapine . European Neuropsychopharmacology 17, 102-107.
16. Baldwin, P.A., Hennessy, R.J., Morgan, M.G. et al. (2004) Controversies in schizophrenia research. In: Gattaz, W.&Hafner, H. eds. Search for the Causes of Schizophrenia . Darmstadt: Steinkopff, pp. 394-409.
17. Baldessarini, R.J., Cohen, B.M.&Teicher M.H.(1988) Signifi cance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Archives of General Psychiatry 45 , 79-91.
18. Bantick, R.A., Montgomery, A.J., Bench, C.J. et al. (2004a) A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. Journal of Psychopharmacology 18, 346-354.
19. Bantick, R.A., Rabiner, E.A., Hirani, E. et al. (2004b) Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology 29, 847-859.
20. Bardin, L., Auclair, A., Kleven, M.S. et al. (2007) Pharmacological profi les in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity. Behavioural Pharmacology 18, 103-118.
21. Barnas, C., Quiner, S., Tauscher, J. et al. (2001) In vivo (123)I IBZM SPECT imaging of striatal dopamine 2 receptor occupancy in schizophrenic patients. Psychopharmacology 157 , 236-242.
22. Barr, A.M., Powell, S.B., Markou, A. et al. (2006) Iloperidone reduces sensorimotor gating defi cits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology 51, 457-465.
23. Basu, A.&Meltzer, H.Y.(2006) Differential trends in prevalence of diabetes and unrelated general medical illness for schizophrenia patients before and after the atypical antipsychotic era. Schizophrenia Research 86, 99-109.
24. Bellack, A.S.(2006) Scientifi c and consumer models of recovery in schizophrenia. Schizophrenia Bulletin 32, 432-442.
25. Bench, C.J., Lammertsma, A.A., Grasby, P.M. et al. (1996) The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography. Psychopharmacology 124 , 141-147.
26. Berger, G.E., Proffitt, T.M., McConchie M. et al.(2007) Ethyl - eicosapentaenoic acid in fi rst-episode psychosis. Journal of Clinical Psychiatry 68, 1867-1875.
27. Berridge, K.C.,&Robinson, T.E.(1998) What is the role of dopamine in reward? Brain Research Reviews 28, 309-369.
28. Bhattacharjee, J.&El-Sayeh, H.G.(2008) Aripiprazole versus typicals for schizophrenia. Cochrane Database Systematic Review , CD006617.
29. Bigliani, V., Mulligan, R.S., Acton, P.D. et al. (1999) In vivo occupancy of striatal and temporal cortical D2/D3 dopamine receptors by typical antipsychotic drugs. British Journal of Psychiatry 175, 231-238.
30. Bigliani, V., Mulligan, R.S., Acton, P.D. et al. (2000) Striatal and temporal cortical D2/D3 receptor occupancy by olanzapine and sertindole in vivo. Psychopharmacology 150, 132-140.
31. Boeckler, F., Russig, H., Zhang, W. et al. (2004) FAUC 213, a highly selective dopamine D4 receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia. Psychopharmacology 175 , 7-17.
32. Bollini, P., Pampaliona, S., Orza, M.J. et al. (1994) Antipsychotic drugs: is more worse? Psychological Medicine 24, 307-316.
33. Bozzi, Y.&Borrelli, E.(2006) Dopamine in neurotoxicity and neuroprotection. Trends in Neuroscience 29, 167-174.
34. Brea, J., Castro, M., Loza, M. I. et al. (2006) QF2004B, a potential antipsychotic butyrophenone derivative with similar pharmacological properties to clozapine. Neuropharmacology 51 , 251-262.
35. Brekke, J.S., Hoe, M., Long, J. et al.(2007) How neurocognition and social cognition infl uence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. Schizophrenia Bulletin 33, 1247-1256.
36. Bressan, R.A., Costa, D.C., Jones, H.M. et al. (2002) Typical antipsychotic drugs: D(2) receptor occupancy and depressive symptoms in schizophrenia. Schizophrenia Research 56, 31-36.
37. Bressan, R.A., Erlandsson, K., Spencer, E.P. et al. (2004) Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients. Psychopharmacology 175, 367-373.
38. Bressan, R.A., Erlandsson, K., Jones, H.M. et al. (2003a) Is regionally selective D2/D3 dopamine occupancy suffi cient for atypical antipsychotic effect? An in vivo quantitative [123I] epidepride SPET study of amisulpride-treated patients. American Journal of Psychiatry 160, 1413-1420.
39. Bressan, R.A., Erlandsson, K., Jones, H.M. et al. (2003b) Optimizing limbic selective D2/D3 receptor occupancy by risperidone. Journal of Clinical Psychopharmacoogyl 23, 5-14.
40. Browman, K.E., Curzon, P., Pan, J.B. et al. (2005) A-412997, a selective dopamine D4 agonist, improves cognitive performance in rats. Pharmacology, Biochemistry&Behavior 82 , 148-155.
41. Buchanan, R.W., Javitt, D.C., Marder, S.R. et al. (2007) The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the effi cacy of glutamatergic agents for negative symptoms and cognitive impairments. American Journal of Psychiatry 164, 1593-1602.
42. Buckley, P.F.&Stahl, S.M.(2007) Pharmacological treatment of negative symptoms of schizophrenia. Acta Psychiatrica Scandinavica 115, 93-100.
43. Buckley, P.F., Mahadik, S., Pillai, A. et al. (2007) Neurotrophins and schizophrenia. Schizophrenia Research 94, 1-11.
44. Burstein, E.S., Ma, J., Wong, S. et al. (2005) Intrinsic effi cacy of antipsychotics at human D2, D3, and D4 dopamine receptors: identifi cation of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. Journal of Pharmacology and Experimental Therapeutics 315, 1278-1287.
45. Bymaster, F.P., Calligaro, D.O., Falcone, J.F. et al. (1996) Radioreceptor binding profi le of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87-96.
46. Byrne, P.(2007) Managing the acute psychotic episode. British Medical Journal 334, 686-692.
47. Caley, C.F.&Weber, S.S.(1995) Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. Annals of Pharmacotherapy 29, 152-160.
48. Carlsson, A.&Lindqvist, A.(1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine in mouse brain. Acta Pharmacologica et Toxicologica 20, 140-144.
49. Carlsson, A.&Carlsson, M.L.(2006) A dopaminergic defi cit hypothesis of schizophrenia. Dialogues in Clinical Neuroscience 8, 137-142.
50. Carlsson, M. L., Carlsson A.,&Nilsson, M.(2004) Schizophrenia: from dopamine to glutamate and back. Current Medicinal Chemistry 11, 267-277.
51. Carpenter, W.T., Conley, R.&Kirkpatrick, B.(2000) On Schizophrenia and new generation drugs. Neuropsychopharmacology 22, 660-661.
52. Castner, S.A.&Williams, G.V.(2007) Tuning the engine of cognition: a focus on NMDA/D1 receptor interactions in prefrontal cortex. Brain and Cognition 63, 94-122.
53. Catts, V.S., Catts, S.V., McGrath, J.J. et al. (2006) Apoptosis and schizophrenia. Schizophrenia Research 84, 20-28.
54. Chintoh, A.F., Mann, S.W., Lam, L. et al. (2008) Insulin resistance and decreased glucose-stimulated insulin secretion after acute olanzapine administration. Journal of Clinical Psychopharmacology 28, 494-499.
55. Chou, Y.H., Halldin C.,&Farde, L.(2003) Occupancy of 5-HT1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology 166, 234-240.
56. Chou, Y.H., Halldin C.,&Farde, L.(2006) Clozapine binds preferentially to cortical D1-like dopamine receptors in the primate brain: a PET study. Psychopharmacology 185, 29-35.
57. Chouinard, G., Annable, L., Ross-Chouinard, A. et al. (1988) A 5-year prospective longitudinal study of tardive dyskinesia. Journal of Clinical Psychopharmacology 8, 21S-26S.
58. Claustre, Y., Peretti, D.D., Brun, P. et al. (2003) SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. Neuropsychopharmacology 28, 2064-2076.
59. Coppens, H.J., Slooff, C.J., Paans, A.M., et al. (1991) High central D2-dopamine receptor occupancy as assessed with positron emission tomography in medicated but therapy - resistant schizophrenic patients. Biological Psychiatry 29 , 629-634.
60. Correll, C.U., Leucht, S.,&Kane, J.M.(2004) Lower risk for tardive dyskinesia associated with second-generation antipsychotics . American Journal of Psychiatry 161, 414-425.
61. Corrigan, M.H., Gallen, C.C., Bonura, M.L. et al. (2004) Effectiveness of the selective D4 antagonist sonepiprazole in schizophrenia. Biological Psychiatry 55, 445-451.
62. Corripio, I., Catafau, A.M., Perez, V. et al. (2005) Striatal dopaminergic D2 receptor occupancy and clinical effi cacy in psychosis exacerbation: a 123I-IBZM study with ziprasidone and haloperidol. Progress in Neuropsychopharmacology and Biological Psychiatry 29, 91-96.
63. Coukell, A.J., Spencer, C.M.&Benfield, P.(1996) Amisulpride: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic effi cacy in the management of schizophrenia . CNS Drugs 6, 237-256.
64. Cousins, D.A.&Young, A.H.(2007) The armamentarium of treatments for bipolar disorder. International Journal of Neuropsychopharmacology 10, 411-431.
65. Coyle, J.T.(2006) Glutamate and schizophrenia: beyond the dopamine hypothesis. Cellular and Molecular Neurobiology 26 , 365-384.
66. Crumb, W.J., Ekins, S. Sarazan, R.D. et al. (2006) Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG. Pharmacological Research 23, 1133-1143.
67. Cucchiaro, J., Nann-Vernotica, R., Lasser, T. et al. (2001) A randomised, double-blind multicenter phase III study of iloperidone versus haloperidol and placebo in patients with schizophrenia or schizoaffective disorder. Schizophrenia Research 49, 223-224.
68. Cuisiat, S., Bourdiol, N., Lacharme, V. et al. (2007) Towards a new generation of potential antipsychotic agents combing D2 and 5-HT1A receptor activities. Journal of Medicinal Chemistry 22, 865-876.
69. Daniel, D.G., Zimbroff, D.L., Potkin, S.G., et al. (1999) Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder. Neuropsychopharmacology 20, 491-505.
70. Davidson, L., Schmutte, T., Dinzeo, T. et al. (2008) Remission and recovery in schizophrenia. Schizophrenia Bulletin 34, 5-8.
71. Davis, K.L., Kahn, R.S., Ko, G. et al. (1991) Dopamine in schizophrenia . American Journal of Psychiatry 148, 1474-1486.
72. Davis, J.M., Chen, N.&Glick I.D.(2003) A meta-analysis of the effi cacy of second-generation antipsychotics. Archives of General Psychiatry 63, 553-564.
73. Dazzan, P., Morgan, K.D., Orr, K. et al. (2005) Different effects of typical and atypical antipsychotics on grey matter in fi rst episode psychosis. Neuropsychopharmacology 30, 765-774.
74. De Beaurepaire, R., Labelle., Naber, D. et al. (1995) An open trial of the D 1 antagonist SCH 39166 in six cases of acute psychotic states. Psychopharmacology 121, 323-327.
75. De Haan, L., Lavalaye, J., van Bruggen, M. et al.(2004) Subjective experience and dopamine D 2 receptor occupancy in patients treated with antipsychotics. Canadian Journal of Psychiatry 49 , 290-296.
76. De Visser, S.J., van der Post, J., Pieters, M.S.M., et al. (2001) Biomarkers for the effects of antipsychotic drugs in healthy volunteers. British Journal of Clinical Pharmacology 51 , 119-132.
77. Den Boer, J.A., van Megen, H.J.G. M., Fleischhacker, W. W. et al. (1995) Differential effects of the D1-DA receptor antagonist SCH 39166 on positive and negative symptoms of schizophrenia . Psychopharmacology 121, 317-322.
78. Deniker, P.(1983) Discovery of the clinical uses of neuroleptics. In: Parnham, M.J.&Bruinvels, J., eds. Discoveries in Pharmacology , Vol. 1. Amsterdam: Elsevier, pp. 163-180.
79. Deutch, A.Y.&Bubser, M.(2007) The orexins/hypocretins and schizophrenia. Schizophrenia Bulletin 33, 1277-1283.
80. Deveney, A.M.&Waddington, J.L.(1997) Psychopharmacological distinction between novel full-effi cacy " D1-like " dopamine receptor agonists. Pharmacology, Biochemstry&Behavior 58 , 551-558.
81. Di Cara, B., Panayi, F., Gobert, A. et al. (2007). Activation of dopamine D1 receptors enhances cholinergic transmission and social cognition. International Journal of Neuropsychopharmacology 10, 383-399.
82. Dickinson, D., Bellack, A.S.,&Gold, J.M.(2007) Social/ communication skills, cognition, and vocational functioning in schizophrenia. Schizophrenia Bulletin 33, 1213-1220.
83. Dunn, C.J.&Fitton, A.(1996) Sertindole. CNS Drugs 5 , 224-230.
84. Ehmann, T.S., Delva, J.J.&Beninger. R.J.(1987) Flupenthixol in chronic schizophrenic inpatients. Journal of Clinical Psychopharmacology 3, 173-175.
85. El-Sayeh, H.G., Morganti C.&Adams, C.E.(2006) Aripiprazole for schizophrenia. British Journal of Psychiatry 189, 102-108.
86. Erlandsson, K., Bressan, R. A., Mulligan, R.S. et al. (2003). Analysis of D2 dopamine receptor occupancy with quantitative SPET using the high-affi nity ligand [123I]epidepride. Neuroimage 19, 1205-1214.
87. Farde, L., Nordstrom, A.L., Wiesel, F.A. et al. (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Archives of General Psychiatry 49, 538-544.
88. Farde, L., Nordstrom, A.L., Nyberg, S. et al. (1994) D1 -, D2 -, and 5-HT2-receptor occupancy in clozapine-treated patients. Journal of Clinical Psychiatry 55(Suppl B), 67-69.
89. Farde, L., Suhara, T., Nyberg, S. et al. (1997) A PET-study of [11C]FLB 457 binding to extrastriatal D2-dopamine receptors in healthy subjects and antipsychotic drug-treated patients. Psychopharmacology 133, 396-404.
90. Feenstra, R.W., de Moes, J., Hofma, J.J. et al. (2001) New 1-aryl - 4-(biarylmethylene)piperazines as potential atypical antipsychotics sharing dopamine D(2)-receptor and serotonin 5-HT(1A)-receptor affi nities. Bioorganic and Medicinal Chemistry Letters 11, 2345-2349.
91. Fischman, A.J., Bonab, A.A., Babich, J.W. et al. (1996) Positron emission tomographic analysis of central 5 - hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone. Journal of Pharmacology&Experimental Therapeutics 279 , 939-947.
92. Fitzgerald, P,&Seeman, P.(1999) Neuroreceptor studies in the elderly. In: Howard, R.&Castle, D., eds. Late-onset Schizophrenia . Philadelphia: Wrightson Biomedical Publishing , pp. 205-216.
93. Franberg, O., Wiker, C., Marcus, M.M. et al. (2008) Asenapine, a novel psychopharmacologic agent. Psychopharmacology 196 , 417-429.
94. Freedman, R.,(2005) The choice of antipsychotic drugs for schizophrenia . New England Journal of Medicine 353, 1286-1288.
95. Fulton, B.&Goa, K.L.(1995) ICI-204,636: an initial appraisal of its pharmacological properties and clinical potential in the treatment of schizophrenia. CNS Drugs 4, 68-78.
96. Gardell, L.R., Vanover, K., E. Pounds, L. et al. (2007) ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic effi cacy and side-effect profi le of haloperidol and risperidone in experimental models. Journal of Pharmacology and Experimental Therapeutics 322, 862-870.
97. Garver, D.L., Holcomb J.A.&Christensen, J.D.(2005) Cerebral cortical gray expansion associated with two second-generation antipsychotics. Biological Psychiatry 58, 62-66.
98. Garver, D.L., Holcomb J.A.&Christensen, J.D.(2008) Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia. International Journal of Neuropsychopharmacology 11, 49-61.
99. Gazi, L., Bobirnac, I., Danzeisen, M. et al.(1999) Receptor density as a factor governing the effi cacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4,4 receptors expressed in CHO cells. British Journal of Pharmacology 128, 613-620.
100. Geddes, J., Freemantle, N., Harrison, P. et al.(2000) Atypical antipsychotics in the treatment of schizophrenia. British Medical Journal 321, 1371-1376.
101. Gefvert, O., Lindstrom, L.H., Dahlback, O. et al.(2000)(-) - OSU6162 induces a rapid onset of antipsychotic effect after a single dose. In: von Knorring, L., ed. Scandinavian Society for Psychopharmacology . Stockholm: Scandinavian Society for Psychopharmacology, pp. 93-94.
102. Gefvert, O., Eriksson, B., Persson, P. et al. (2005) Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. International Journal of Neuropsychopharmacology 8, 27-36.
103. Gefvert, O., Lundberg, T., Wieselgren, I.M. et al. (2001) D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. European Neuropsychopharmacology 11, 105-110.
104. George, M.S., Molnar, C.E., Grenesko, E.L. et al. (2007) A single 20 mg dose of dihydrexidine (DAR-0100), a full dopamine D1 agonist, is safe and tolerated in patients with schizophrenia. Schizophrenia Research 93, 42-50.
105. Geyer, M.A.&Ellenbroek, B.(2003) Animal behavior models of the mechanisms underlying antipsychotic atypicality. Progress in Neuropsychopharmacology&Biological Psychiatry 27 , 1071-1079.
106. Glantz, L.A., Gilmore, J.E., Lieberman, J.A. et al.(2006) Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophrenia Research 81, 47-63.
107. Goeree, R., Farahati, F., Burke, N. et al.(2005) The economic burden of schizophrenia in Canada in 2004. Current Medical Research and Opinion 21, 2017-2028.
108. Gogos, J.A.(2007) Schizophrenia susceptibility genes. International Review of Neurobiology 78, 397-422.
109. Gray, J.A.&Roth, B.L.(2007) Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophrenia Bulletin 33, 1100-1119.
110. Green, M.F.&Nuechterlein, K.H.(1999) Should schizophrenia be treated as a neurocognitive disorder? Schizophrenia Bulletin 25, 309-319.
111. Green, M.F.&Nuechterlein, K.H.(2004) The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophrenia Research 72, 1-3.
112. Green, M.F., Penn, D.L., Bentall, R. et al.(2008) Social cognition in schizophrenia. Schizophrenia Bulletin 34, 1211-1220.
113. Greenwood, K.E., Landau, S.&Wykes, T.(2005) Negative symptoms and specifi c cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophrenia Bulletin 31, 910-921.
114. Grunder, G., Carlsson A.&Wong, D.F.(2003) Mechanism of new antipsychotic medications. Archives of General Psychiatry 60, 974-977.
115. Grunder, G., Landvogt, C., Vernaleken, I. et al. (2006) The striatal and extrastriatal D2/D3 receptor-binding profi le of clozapine in patients with schizophrenia. Neuropsychopharmacology 31 , 1027-1035.
116. Guillin, O., Abi-Dargham, A.&Laruelle, M.(2007) Neurobiology of dopamine in schizophrenia. International Review of Neurobiology 78, 1-39.
117. Haddad, P.M.&Sharma, S.G.(2007) Adverse effects of atypical antipsychotics. CNS Drugs 21, 911-936.
118. Hamamura, T.&Harada, T.(2007) Unique pharmacological profi le of aripiprazole as the phasic component buster. Psychopharmacology 191, 741-743.
119. Hansen, H.H., Timmermann, D.B., Peters, D. et al. (2007) Alpha - 7 nicotinic acetylcholine receptor agonists selectively activate limbic regions of the rat forebrain. Journal of Neuroscience Research 85, 1810-1818.
120. Harvey, P.D., Koren, D., Reichenberg, A. et al.(2006) Negative symptoms and cognitive defi cits. Schizophrenia Bulletin 32 , 250-258.
121. Hertel, P.(2006) Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action. Synapse 60, 543-552.
122. Hertel, P., Didriksen, M., Pouzet, B. et al. (2007) Lu 35-138 (( ??)-(S)-3-{1-[2-(1-acetyl-2,3-dihydro-1H-indol-3-yl)ethyl]-3,6 - dihydro-2H-pyridin-4-yl}-6-chloro-1H-indole), a dopamine D4 receptor antagonist and serotonin reuptake inhibitor. European Journal of Pharmacology 573, 148-160.
123. Heusler, P., Newman-Tancredi, A., Castro-Fernandez, A. et al. (2007) Differential agonist and inverse agonist profi le of antipsychotics at D 2L receptors coupled to GIRK potassium channels . Neuropharmacology 52, 1106-1113.
124. Hippius, H.(1989) The history of clozapine. Psychopharmacology 99, S3-S5.
125. Houseknecht, K.L., Robertson, A.S., Zavadoski, W. et al.(2006) Acute effects of atypical antipsychotics on whole-body insulin resistance in rats. Neuropsychopharmacology 32, 289-297.
126. Hrib, N.J.(2000) The dopamine D 4 receptor. Drugs of the Future 25, 587-611.
127. Ichikawa, J., Li, Z., Dai, J. et al. (2002) Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Research 956, 349-357.
128. Javitt, D. C.(2008) Glycine transport inhibitors and the treatment of schizophrenia. Biological Psychiatry 63, 6-8.
129. Jenner, P., Theodorou A.&Marsden, C.D.(1982) Specifi c receptors for substituted benzamide drugs in brain. Advances in Biochemical Psychopharmacology 35, 109-141.
130. Johnstone, E.C., Crow, T.J., Frith, C.D. et al.(1978) Mechanism of antipsychotic effect in the treatment of acute schizophrenia. Lancet 1, 848-851.
131. Johnstone, E.C., Crow, T.J., Frith, C.D. et al.(1988) The Northwick parkfunctional'psychosis study. Lancet 2, 119-125.
132. Jones, H.M.&Pilowsky, L.S.(2002) Dopamine and antipsychotic drug action revisited. British Journal of Psychiatry 181 , 271-275.
133. Jones, H.M., Travis, M.J., Mulligan, R. et al. (2001) In vivo 5-HT2A receptor blockade by quetiapine. Psychopharmacology 157 , 60-66.
134. Jones, P.B., Barnes, T.R., Davies, L. et al. (2006) Randomized controlled trial of the effect on Quality of Life of second-vs fi rst-generation antipsychotic drugs in schizophrenia. Archives of General Psychiatry 63, 1079-1087.
135. Jorgensen, A.W., Hilden J.&Gotzsche, P.C.(2006) Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs. British Medical Journal 333, 782.
136. Joyce, J.N.&Millan, M.J.(2005) Dopamine D3 receptor antagonists as therapeutic agents. Drug Discovery Today 10 , 917-925.
137. Kahn, R.S., Schulz, S.C., Palazov, V.D. et al. (2007) Effi cacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia. Journal of Clinical Psychiatry 68 , 832-842.
138. Kales, H.C., Valenstein, M., Kim, H.M. et al.( 2007) Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. American Journal of Psychiatry 164, 1568-1576.
139. Kalkman, H.O., Subramanian N.&Hoyer, D.(2001) Extended radioligand binding profi le of iloperidone. Neuropsychopharmacology 25, 904-914.
140. Kane, J.M., Carson, W.H., Saha, A.R. et al.(2002) Effi cacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. Journal of Clinical Psychiatry 63, 763-771.
141. Kane, J., Canas, F., Kramer, M. et al. (2007) Treatment of schizophrenia with paliperidone extended-release tablets. Schizophrenia Research 90, 147-161.
142. Kane, J., Honigfield, G., Singer, J., et al. (1988) Clozapine for the treatment-resistant schizophrenic. Archives of General Psychiatry 45, 789-796.
143. Kapur, S.&Remington, G.(1996) Serotonin-dopamine interaction and its relevance to schizophrenia. American Journal of Psychiatry 153, 466-476.
144. Kapur, S.&Seeman, P.(2000) Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Journal of Psychiatry and Neuroscience 25, 161-166.
145. Kapur, S.(2000) Receptor occupancy by antipsychotics. In: Lidow, M.S., ed. Neurotransmitter Receptors in Actions of Antipsychotics . London: CRC Press, pp. 163-176.
146. Kapur, S.(2003) Psychosis as a state of aberrant salience. American Journal of Psychiatry 160, 13-23.
147. Kapur, S.(2004) How antipsychotics become anti-" psychotic ". Trends in Pharmacological Science 25, 402-406.
148. Kapur, S.&Mamo, D.(2003) Half a century of antipsychotics and still a central role for dopamine D2 receptors. Progress in Neuropsychopharmacology and Biological Psychiatry 27, 1081-1090.
149. Kapur, S.&Remington, G.(2001) Dopamine D(2) receptors and their role in atypical antipsychotic action. Biological Psychiatry 50, 873-883.
150. Kapur, S.,&Seeman, P.(2001) Does fast dissociation from the dopamine D 2 receptor explain the action of atypical antipsychotics? American Journal of Psychiatry 158, 360-369.
151. Kapur, S., Agid, O., Mizrahi, R. et al. (2006) How antipsychotics work. NeuroReceptor 3, 10-21.
152. Kapur, S., Mizrahi, R.&Li, M.(2005) From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophrenia Research 79, 59-68.
153. Kapur, S., Remington, G., Jones, C. et al. (1996) High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment. American Journal of Psychiatry 153, 948-950.
154. Kapur, S., Remington, G., Zipursky, R.B. et al.(1995) The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms. Life Sciences 57, 103-107.
155. Kapur, S., Zipursky, R.B.&Remington, G.(1999) Clinical and theoretical implications of 5-HT 2 and D 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. American Journal of Psychiatry 156, 286-293.
156. Kapur, S., Zipursky, R., Jones, C. et al.(2000a) Relationship between dopamine D(2) occupancy, clinical response, and side effects. American Journal of Psychiatry 157, 514-520.
157. Kapur, S., Zipursky, R., Jones, C. et al.(2000c) A positron emission tomography study of quetiapine in schizophrenia. Archives of General Psychiatry 57, 553-559.
158. Kapur, S., Zipursky, R., Remington, G. et al.(2000b) Fast Koff at the dopamine D2 receptor (not high affi nity at other receptors) is the key to clozapine's uniqueness and atypical antipsychotic activity. International Journal of Neuropsychopharmacology 3 (Suppl 1), S95.
159. Kapur, S., Zipursky, R.B., Remington, G. et al. (1998) 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia. American Journal of Psychiatry 55, 921-928.
160. Karle, J., Clemmesen, L., Hansen, L. et al.(1995) NNC 01-0687, a selective dopamine D1 receptor antagonist, in the treatment of schizophrenia. Psychopharmacology 121, 328-329.
161. Karlsson, P., Smith, L., Farde, L. et al.(1995) Lack of apparent antipsychotic effect of the D 1-dopamine receptor antagonist SCH 39166 in acutely ill schizophrenic patients. Psychopharmacology 121, 309-316.
162. Kasper, S., Tauscher, J., Kufferle, B. et al. (1998) Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol. Psychopharmacology 136 , 367-373.
163. Kebabian, J.W.&Calne, D.B.(1979) Multiple receptors for dopamine. Nature 277, 93-96.
164. Kessler, R.M., Ansari, M.S., Riccardi, P. et al. (2005) Occupancy of striatal and extrastriatal dopamine D2/D3 receptors by olanzapine and haloperidol. Neuropsychopharmacology 30 , 2283-2289.
165. Kessler, R.M., Ansari, M. S., Riccardi, P. et al. (2006) Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31, 1991-2001.
166. Kim, S.F., Huang, A.S., Snowman, A.M. et al. (2007) Antipsychotic drug-induced weight gain mediated by histamine H1 receptor - linked activation of hypothalamic AMP-kinase. Proceedings of the National Acadamy of Sciences USA 104, 3456-3459.
167. Kippin, T.E., Kapur S.&van der Kooy, D.(2005) Dopamine specifi cally inhibits forebrain neural stem cell proliferation, suggesting a novel effect of antipsychotic drugs. Journal of Neuroscience 25, 5815-5823.
168. Koike, K., Hashimoto, K., Takai, N. et al.(2005) Tropisetron improves defi cits in auditory P50 suppression in schizophrenia . Schizophrenia Research 76, 67-72.
169. Kongsamut, S., Kang, J., Chen, X.L. et al. (2002) A comparison of the receptor binding and HERG channel affi nities for a series of antipsychotic drugs. European Journal of Pharmacology 450 , 37-41.
170. Kornhuber, J., Wiltfang, J., Riederer, P. et al. (2006). Neuroleptic drugs in the human brain: clinical impact of persistence and region-specifi c distribution. European Archives of Psychiatry&Clinical Neuroscience 256, 274-280.
171. Kramer, M.S., Last, B., Getson, A. et al.(1997) The effects of a selective D 4 dopamine receptor antagonist (L-745,870) in acutely psychotic inpatients with schizophrenia. Archives of General Psychiatry 54, 567-572.
172. Labelle, A., de Beaurepaire, R., Boulay, L.J. et al. (1998) A pilot study of the safety and tolerance of SCH 39166 in patients with schizophrenia. Journal of Psychiatry&Neuroscience 23 , 93-94.
173. Lahti, R.A., Tamminga C.A.&Carlsson, A.(2007) Stimulating and inhibitory effects of the dopamine " stabilizer "(-)-OSU6162 on dopamine D(2) receptor function in vitro. Journal of Neural Transmission 114, 1143-1146.
174. Lambe, E.K., Liu R.J.&Aghajanian, G.K.(2007) Schizophrenia, hypocretin (orexin), and the thalamocortical activating system. Schizophrenia Bulletin 33, 1284-1290.
175. Lameh, J., Burstein, E.S., Taylor, E. et al. (2007) Pharmacology of N-desmethylclozapine. Pharmacology and Therapeutics 115 , 223-231.
176. Lane, H.Y., Chang, Y.C., Liu, Y.C. et al. (2005) Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia . Archives of General Psychiatry 62, 1196-1204.
177. Lane, H.Y., Liu, Y.C., Huang, C.L. et al. (2008) Sarcosine (N-methylglycine) treatment for acute schizophrenia. Biological Psychiatry 63, 9-12.
178. Laughren, T.&Levin, R.(2006) Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim. Schizophrenia Bulletin 32 , 220-222.
179. Lawler, C.P., Prioleau, C., Lewis, M.M. et al.(1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20, 612-627.
180. Lawrence, A.J.(2007) Optimisation of anti-psychotic therapeutics . British Journal of Pharmacology 151, 161-162.
181. Lester, H.&Gask, L.(2006) Delivering medical care for patients with serious mental illness or promoting a collaborative model of recovery? British Journal of Psychiatry 188, 465-471.
182. Leucht, S., Pitschel-Walz, G., Engel, R.R. et al. (2002) Amisulpride, an unusual " atypical " antipsychotic. American Journal of Psychiatry 159, 180-190.
183. Leucht, S., Engel, R.R., Bauml, J. et al. (2007) Is the superior effi cacy of new generation antipsychotics an artifact of LOCF? Schizophrenia Bulletin 33, 183-191.
184. Leucht, S., Wahlbeck, K., Hamann, J. et al.(2003) New generation antipsychotics versus low-potency conventional antipsychotics . Lancet 361, 1581-1589.
185. Levant, B.(1997) The D3 dopamine receptor. Pharmacological Reviews 49, 231-252.
186. Levkovitz, Y., Levi, U., Braw, Y. et al. (2007) Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia. Brain Research 1154 , 154-162.
187. Lewis, D.A.&Gonzalez-Burgos, G.(2006) Pathophysiologically based treatment interventions in schizophrenia. Nature Medicine 12, 1016-1022.
188. Lewis, R., Bagnall A. M.&Leitner, M.(2005) Sertindole for schizophrenia. Cochrane Database Systematic Reviews CD001715.
189. Li, Z., Ichikawa, J., Dai, J. et al. (2004) Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. European Journal of Pharmacology 493, 75-83.
190. Lidsky, T.I.(1995) Reevaluation of the mesolimbic hypothesis of antipsychotic drug action. Schizophrenia Bulletin 21 , 67-74.
191. Lieberman, J.A., Stroup, T.S., McEvoy, J.P. et al. (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353 , 1209-1223.
192. Lindstrom, E., Farde, L., Eberhard, J. et al. (2005) QTc interval prolongation and antipsychotic drug treatments. International Journal of Neuropsychopharmacology 8, 615-629.
193. Liu, I.S.C., George, S.R.&Seeman, P.(2000) The human D2 Longer receptor has a high-affi nity state and inhibits adenylyl cyclase. Molecular Brain Research 77, 281-284.
194. Mamo, D., Graff, A., Mizrahi, R. et al. (2007) Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia. American Journal of Psychiatry 164, 1411-1417.
195. Mamo, D., Kapur, S., Shammi, C.M. et al. (2004) A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. American Journal of Psychiatry 161, 818-825.
196. Mamo, D., Kapur, S., Keshavan, M. et al. (2008a) D2 receptor occupancy of olanzapine pamoate depot using positron emission tomography. Neuropsychopharmacology 33, 298-304.
197. Mamo, D.C., Uchida, H., Vitcu, I. et al. (2008b) Quetiapine extended-release versus immediate-release formulation. Journal of Clinical Psychiatry 69, 81-86.
198. Marder, S.R.&Fenton, W.(2004) Measurement And Treatment Research to Improve Cognition in Schizophrenia. Schizophrenia Research 72, 5-9.
199. Marder, S.R.(2006a) Drug initiatives to improve cognitive function . Journal of Clinical Psychiatry 67(Suppl. 9), 31-35.
200. Marder, S.R.(2006b) Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness. Journal of Clinical Psychiatry 67, e03.
201. Marder, S.R., Kramer, M., Ford, L. et al. (2007) Effi cacy and safety of paliperidone extended-release tablets. Biological Psychiatry 62, 1363-1370.
202. Marquis, K.L., Sabb, A.L., Logue, S.F. et al. (2007) WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b] [1,4]diazepino[ 6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic - like activity. Journal of Pharmacology and Experimental Therapeutics 320, 486-496.
203. Martinot, J.L., Pailliere-Martinot, M.L., Poirier, M.F. et al.(1996) In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology 124 , 154-158.
204. Mauri, M.C., Bravin, S., Bitetto, A. et al. (1996) A risk-benefi t assessment of sulpiride in the treatment of schizophrenia. Drug Safety 14, 288-298.
205. McCormick, P.N., Kapur, S., Seeman, P. et al. (2008) Dopamine D2 receptor radiotracers [ (11) C]( ??)-PHNO and [ (3) H] raclopride are indistinguishably inhibited by D 2 agonists and antagonists ex vivo . Nuclear Medicine and Biology 35, 11-17.
206. McCreary, A.C., Glennon, J.C., Ashby, C.R. et al. (2007) SLV313 (1-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-4-[5-(4-fl uoro-phenyl) - pyridin-3-ylmethyl]-piperazine monohydrochloride): a novel dopamine D2 receptor antagonist and 5-HT1A receptor agonist potential antipsychotic drug. Neuropsychopharmacology 32, 78-94.
207. McEvoy, J.P., Lieberman, J.A., Stroup, T.S. et al. (2006) Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163, 600-610.
208. McGlashan, T.H.,(2006) Is active psychosis neurotoxic? Schizophrenia Bulletin 32, 609-613.
209. McGlashan, T.H., Zipursky, R.B., Perkins, D. et al. (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. American Journal of Psychiatry 163, 790-799.
210. McGorry, P.D., Yung, A.R., Philips, L.J. et al. (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to fi rst-episode psychosis in a clinical sample with subthreshold symptoms. Archives of General Psychiatry 59 , 921-928.
211. McKeage, K.&Plosker, G.L.(2004) Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 18 , 933-956.
212. Mehta, M.A., Montgomery, A.J., Kitamura, Y. et al. (2008) Dopamine D2 receptor occupancy levels of acute sulpiride challenges that produce working memory and learning impairments in healthy volunteers. Psychopharmacology 196 , 157-165.
213. Meltzer, H.(1995) Atypical antipsychotic drugs. In: Kupfer, D.&Bloom, F.E., eds. Psychopharmacology: The Fourth Generation of Progress . New York: Raven Press, pp. 1277-1286.
214. Meltzer, H.Y.(2007) Iluminating the molecular basis for some antipsychotic drug-induced metabolic burden. Proceedings of the National Acadamy of Sciences USA 104, 3019-3020.
215. Meltzer, H.Y., Arvanitis, L., Bauer, D. et al. (2004) Placebo - controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. American Journal of Psychiatry 161, 975-984.
216. Meltzer, H.Y., Li, Z., Kaneda, Y. et al. (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Progress in Neuropsychopharmacology and Biological Psychiatry 27 , 1159-1172.
217. Meltzer, H.Y., Matsubara, S.&Lee, J-C.(1989) Classifi cation of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. Journal of Pharmacology and Experimental Therapeutics 251, 238-246.
218. Metzger, K.L., Shoemaker, J.M., Kahn, J.B. et al. (2007) Pharmacokinetic and behavioral characterization of a long - term antipsychotic delivery system in rodents and rabbits. Psychopharmacology 190, 201-211.
219. Millan, M.J., Svenningsson, P., Ashby, C.R. et al. (2008) S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] - benzopyrano[3,4-c]pyrr ol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent. Journal of Pharmacology and Experimental Therapeutics 324, 600-611.
220. Missale, C., Nash, S.R., Robinson, S.W. et al. (1998) Dopamine receptors: from structure to function. Physiological Reviews 78 , 189-225.
221. Mitchell, K., Runker, A., Little, G. et al.(2008) Semaphorin and plexin genes specify limbic and cortical connectivity and are implicated in the etiology of schizophrenia. Schizophrenia Research 102(Suppl. 2), 26-27.
222. Miyamoto, S., Duncan, G.E., Marx, C.E. et al. (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 10, 79-104.
223. Miyaoka, T., Yasukawa, R., Yasuda, H. et al. (2007) Possible antipsychotic effects of minocycline in patients with schizophrenia . Progress in Neuropsychopharmacology and Biological Psychiatry 31, 304-307.
224. Mizrahi, R., Bagby, R.M., Zipursky, R.B. et al. (2005) How antipsychotics work. Progress in Neuropsychopharmacology and Biological Psychiatry 29, 859-864.
225. Mizrahi, R., Kiang, M., Mamo, D.C., et al. (2006) The selective effect of antipsychotics on the different dimensions of the experience of psychosis in schizophrenia spectrum disorders. Schizophrenia Research 88, 111-118.
226. Mizrahi, R., Rusjan, P., Agid, O. et al. (2007) Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors. American Journal of Psychiatry 164, 630-637.
227. Molina, V., Reig, S., Sanz, J. et al. (2005) Increase in gray matter and decrease in white matter volumes in the cortex during treatment with atypical neuroleptics in schizophrenia. Schizophrenia Research 80, 61-71.
228. Molitch, M.(1995) Prolactin. In: Molitch, M., ed. The Pituitary . pp 136-183. Oxford: Blackwell, pp. 136-183.
229. Moller, H.J.,(2003) Amisulpride: limbic specifi city and the mechanism of antipsychotic atypicality. Progress in Neuropsychopharmacology and Biological Psychiatry 27 , 1101-1111.
230. Moller, H.J.,(2007) Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs 67 , 1541-1566.
231. Morein-Zamir, S., Turner D.C.&Sahakian, B.J.(2007) A review of the effects of modafi nil on cognition in schizophrenia. Schizophrenia Bulletin 33, 1298-1306.
232. Mota, N.E., Lima M.S.&Soares, B.G.(2002) Amisulpride for schizophrenia. Cochrane Database Systematic Reviews CD001357.
233. Mu, Q., Johnson, K., Morgan, P.S. et al. (2007) A single 20 mg dose of the full D1 dopamine agonist dihydrexidine (DAR - 0100) increases prefrontal perfusion in schizophrenia. Schizophrenia Research 94, 332-341.
234. Murdoch, D.&Keating, G.M.(2006) Sertindole. CNS Drugs 20 , 233-255.
235. Murphy, B.P., Chung, Y.C., Park, T.W. et al. (2006) Pharmacological treatment of primary negative symptoms in schizophrenia. Schizophrenia Research 88, 5-25.
236. Nagai, T., Noda, Y., Une, T. et al. (2003) Effect of AD-5423 on animal models of schizophrenia. Neuroreport 14, 269-272.
237. Nasrallah, H.A.,(2008) Atypical antipsychotic-induced metabolic side effects. Molecular Psychiatry 13, 27-35.
238. Natesan, S., Reckless, G.E., Nobrega, J.N. et al. (2006a) Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31, 1854-1863.
239. Natesan, S., Svensson, K. A., Reckless, G. E. et al. (2006b) The dopamine stabilizers (S) -(-)-(3-methanesulfonyl-phenyl) - 1-propyl-piperidine [( -)-OSU6162] and 4-(3-methanesulfonyl phenyl)-1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like effi cacy, and low potential for motor side effects in the rat. Journal of Pharmacology and Experimental Therapeutics 318, 810-818.
240. Natesan, S., Reckless, G. E., Barlow, K. B. et al. (2007) Evaluation of N-desmethylclozapine as a potential antipsychotic - preclinical studies. Neuropsychopharmacology 32, 1540-1549.
241. Newman-Tancredi, A., Cussac D.&Depoortere, R.(2007a) Neuropharmacological profi le of bifeprunox. Current Opinion on Investigational Drugs 8, 539-554.
242. Newman-Tancredi, A., Assie, M.B., Martel, J.C. et al. (2007b) F15063, a potential antipsychotic with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. British Journal of Pharmacology 151, 237-252.
243. Newman-Tancredi, A., Heusler, P., Martel, J.C. et al. (2008) Agonist and antagonist properties of antipsychotics at human dopamine D4.4 receptors. International Journal of Neuropsychopharmacolgy 11, 293-307.
244. Niemegeers, C.J.E.&Janssen, P.A.J.(1978) A systematic study of the pharmacological activities of dopamine antagonists. Life Sciences 24, 2201-2216.
245. Nihalani, N.D., Tu, X., Lamberti, J.S., et al. (2007) Diabetic ketoacidosis among patients receiving clozapine. Annals of Clinical Psychiatry 19, 105-112.
246. Niznik, H.B., Sugamori, K.S., Clifford, J.J. et al. (2002) D 1-like dopamine receptors. In: Di Chiara, G., ed. Handbook of Experimental Pharmacology: Dopamine in the CNS . Heidelberg , Springer, pp. 121-158.
247. Nordstrom, A.L., Farde, L., Nyberg, S. et al. (1995) D 1, D 2, and 5-HT 2 receptor occupancy in relation to clozapine serum concentration . American Journal of Psychiatry 152, 1444-1449.
248. Nordstrom, A.L.&Farde, L.(1998) Plasma prolactin and central D2 receptor occupancy in antipsychotic drug-treated patients. Journal of Clinical Psychopharmacology 18, 305-310.
249. Nordstrom, A.L., Farde, L., Wiesel, F.A. et al. (1993) Central D2 - dopamine receptor occupancy in relation to antipsychotic drug effects. Biological Psychiatry 33, 227-235.
250. Nordstrom, A.L., Mansson, M., Jovanovic, H. et al( 2008) PET analysis of the 5HT 2A receptor inverse agonist ACP-103 in human brain. International Journal of Neuropsychopharmacology 11, 163-171.
251. Nyberg, S., Farde, L., Halldin, C., et al. (1995) D2 dopamine receptor occupancy during low-dose treatment with haloperidol decanoate. American Journal of Psychiatry 152 , 173-178.
252. Nyberg, S., Olsson, H., Nilsson, U. et al. (2002) Low striatal and extra-striatal D2 receptor occupancy during treatment with the atypical antipsychotic sertindole. Psychopharmacology 162 , 37-41.
253. Nyberg, S., Nakashima, Y., Nordstrom, A.L. et al. (1996) Positron emission tomography of in-vivo binding characteristics of atypical antipsychotic drugs. British Journal of Psychiatry 168 (Suppl. 29), 40-44.
254. O'Connor, S.E.&Brown, R.A.(1982) The pharmacology of sulpiride. General Pharmacology 13, 185-193.
255. O'Hara, P., Brugha, T.S., Lesage, A. et al. (1993) New fi ndings on tardive dyskinesia in a community sample. Psychological Medicine 23, 453-465.
256. O'Tuathaigh, C.M.P., Babovic, D., O'Meara, G. et al. (2007) Susceptibility genes for schizophrenia: phenotypic characterisation of mutant models. Neuroscience&Biobehavioural Reviews 31, 60-78.
257. Olincy, A., Harris, J.G., Johnson, L.L. et al. (2006) Proof-of - concept trial of an alpha7 nicotinic agonist in schizophrenia. Archives of General Psychiatry 63, 630-638.
258. Olsson, H.&Farde, L.(2001) Potentials and pitfalls using high affi nity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy. NeuroImage 14 , 936-945.
259. Pariante, C.M., Dazzan, P., Danese, A., et al. (2005) Increased pituitary volume in antipsychotic-free and antipsychotic - treated patients of the AESOP fi rst-onset psychosis study. Neuropsychopharmacology 30, 1923-1931
260. Park, W.K., Jeong, D., Cho, H. et al. (2005) KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affi nity, exhibits antipsychotic properties in animal models of schizophrenia. Pharmacology, Biochemistry&Behavior 82 , 361-372.
261. Patel, M.V., Kolasa, T., Mortell, K. et al. (2006) Discovery of 3-methyl-N-(1-oxy-3 '?,4 '?,5 '?,6 '?- tetrahydro-2 '?H-[2,4 '?- bipyridine] - 1 '?- ylmethyl)benzamide (ABT-670), an orally bioavailable dopamine D4 agonist for the treatment of erectile dysfunction. Journal of Medicinal Chemistry 49, 7450-7465.
262. Patil, S.T., Zhang, L., Martenyi, F. et al. (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia. Nature Medicine 13, 1102-1107.
263. Penn, D.L., Waldheter, E.J., Perkins, D.O. et al. (2005) Psychosocial treatment for fi rst-episode psychosis. American Journal of Psychiatry 162, 2220-2232.
264. Perrault, G.H., Depoortere, R., Morel, E. et al. (1997) Psychopharmacological profi le of amisulpride. Journal of Pharmacology and Experimental Therapeutics 280, 73-82.
265. Petersen, L., Jeppesen, P., Thorup, A. et al. (2005) A randomised multicentre trial of integrated versus standard treatment for patients with a fi rst episode of psychotic illness. British Medical Journal 331, 602.
266. Peuskens, J., Moore, N., Azorin, J.M. et al. (2007) The European sertindole safety and exposure survey. Pharmacoepidemiology of Drug Safety 16, 804-811.
267. Pichat, P., Bergis, O.E., Terranova, J.P. et al. (2007) SSR180711, a novel selective alpha7 nicotinic receptor partial agonist. Neuropsychopharmacology 32, 17-34
268. Pilowsky, L. S., Bressan, R. A., Stone, J. M. et al. (2006) First in vivo evidence of an NMDA receptor defi cit in medication-free schizophrenic patients. Molecular Psychiatry 11, 118-119.
269. Pilowsky, L.S., Busatto, G.F., Taylor, M. et al. (1996) Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine. Psychopharmacology 124, 148-153.
270. Pilowsky, L.S., Mulligan, R.S., Acton, P.D. et al. (1997a) Limbic selectivity of clozapine. Lancet 350, 490-491.
271. Pilowsky, L.S., O'Connell, P., Davies, N. et al. (1997b) In vivo effects on striatal dopamine D 2 receptor binding by the novel atypical antipsychotic drug sertindole. Psychopharmacology 130, 152-158.
272. Potkin, S. G., Cohen M.&Panagides, J.(2007) Effi cacy and tolerability of asenapine in acute schizophrenia. Journal of Clinical Psychiatry 68, 1492-1500.
273. Prakash, A.&Lamb, H.M.(1998) Zotepine. CNS Drugs 9 , 153-175.
274. Raedler, T.J., Knable, M.B., Jones, D.W. et al. (2000) In vivo olanzapine occupancy of muscarinic acetylcholine receptors in patients with schizophrenia. Neuropsychopharmacology 23 , 56-68.
275. Raedler, T.J., Knable, M.B., Jones, D.W. et al. (2003) Central muscarinic acethylcholine receptor availability in patients treated with clozapine. Neuropsychopharmacology 28, 1531-1537.
276. Raedler, T. J.(2007) Comparison of the in-vivo muscarinic cholinergic receptor availability in patients treated with clozapine and olanzapine. International Journal of Neuropsychopharmacology 10, 275-280.
277. Ramankutty, G.(2002) Olanzapine-induced destabilization of diabetes in the absence of weight gain. Acta Psychiatrica Scandinavica 105, 237-236.
278. Ramaswamy, K., Kozma, C. M.&Nasrallah, H.(2007) Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine . Drug Safety 30, 589-599.
279. Rampe, D., Murawsky, M.K., Grau, J. et al. (1998) The antipsychotic agent sertindole is a high affi nity antagonist of the human cardiac potassium channel HERG. Journal of Pharmacology and Experimental Therapeutic s 286, 788-793.
280. Reif, A., Schmitt, A., Fritzen, S. et al. (2007) Neurogenesis and schizophrenia. European Archives of Psychiatry and Clinical Neuroscience 257, 290-299.
281. Reimold, M., Solbach, C., Noda, S. et al. (2007) Occupancy of dopamine D(1), D (2) and serotonin (2A) receptors in schizophrenic patients treated with fl upentixol in comparison with risperidone and haloperidol. Psychopharmacology 190 , 241-249.
282. Remington, G., Mamo, D., Labelle, A. et al. (2006) A PET study evaluating dopamine D2 receptor occupancy for long-acting injectable risperidone. American Journal of Psychiatry 163 , 396-401.
283. Remington, G., Kapur, S.&Zipursky, R.B.(1998) Pharmacotherapy of fi rst-episode schizophrenia. British Journal of Psychiatry 172 (Suppl.), 66-70.
284. Richelson, E.&T. Souder,(2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds . Life Science 68, 29-39.
285. Richtand, N.M., Welge, J.A., Logue, A.D. et al. (2007) Dopamine and serotonin receptor binding and antipsychotic effi cacy. Neuropsychopharmacology 32, 1715-1726.
286. Rorick-Kehn, L.M., Johnson, B.G., Knitowski, K.M., et al. (2007) In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders. Psychopharmacology 193, 121-136.
287. Rosenheck, R.A.(2006) Outcomes, costs, and policy caution. Archives of General Psychiatry 63, 1074-1076.
288. Rosenheck, R., Perlick, D., Bingham, S. et al. (2003) Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia. Journal of the American Medical Association 290 , 2693-2702.
289. Ross, C.A., Margolis, R.L., Reading, S.A. et al. (2006) Neurobiology of schizophrenia. Neuron 52, 139-153.
290. Rung, J.P., Carlsson, A., Markinhuhta, K.R. et al. (2005) The dopaminergic stabilizers(-)-OSU6162 and ACR16 reverse (??)-MK-801-induced social withdrawal in rats. Progress in Neuropsychopharmacology and Biological Psychiatry 29 , 833-839.
291. Saeedi, H., Remington, G.&Christensen, B.K.(2006) Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophrenia Research 85, 222-231.
292. Samaha, A.N., Reckless, G.E., Seeman, P. et al. (2008) Less is more: antipsychotic drug effects are greater with transient rather than continuous delivery. Biological Psychiatry 64 , 145-152.
293. Seamans, J.K.&Yang, C.R.(2004) The principle features and mechanisms of dopamine modulation in the prefrontal cortex. Progress in Neurobiology 74, 1-58.
294. Scherk, H., Pajonk F.G.&Leucht, S.(2007) Second-generation antipsychotic agents in the treatment of acute mania. Archives of General Psychiatry 64, 442-455.
295. Schneider, L.S., Dagerman K.S.&Insel, P.(2005) Risk of death with atypical antipsychotic drug treatment for dementia. Journal of the American Medical Association 294, 1934-1943.
296. Schoemaker, H., Claustre, Y., Fage, D. et al. (1997) Neurochemical characteristics of amisulpride, an atypical dopamine D 2 /D 3 receptor antagonist with both presynaptic and limbic selectivity . Journal of Pharmacology and Experimental Therapeutic s 280 , 83-97.
297. Schotte, A., Janssen, P.F., Gommeren, W. et al. (1996) Risperidone compared with new and reference antipsychotic drugs. Psychopharmacology 124, 57-73.
298. Schultz, W.(2002). Getting formal with dopamine and reward. Neuron 36, 241-263.
299. Schultz, W.(2007) Multiple dopamine functions at different time courses. Annual Review of Neuroscience 30, 259-288.
300. Seeger, T.F., Seymour, P.A., Schmidt, A.W. et al. (1995) Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Journal of Pharmacology&Experimental Therapeutics 275, 101-113.
301. Seeman, P.&Tallerico, T.(1998) Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Molecular Psychiatry 3, 123-134.
302. Seeman, P.&Tallerico, T.(1999) Rapid release of antipsychotic drugs from dopamine D 2 receptors. American Journal of Psychiatry 156, 876-884.
303. Seeman, P.(1980) Brain dopamine receptors. Pharmacological Reviews 32, 229-313.
304. Seeman, P.(1992) Dopamine receptor sequences: therapeutic levels of neuroleptics occupy D 2 receptors, clozapine occupies D 4. Neuropsychopharmacology 7, 261-284.
305. Seeman, P.&Guan, H. C.(2007) Dopamine partial agonist action of(-)OSU6162 is consistent with dopamine hyperactivity in psychosis. European Journal of Pharmacology 557, 151-153.
306. Seeman, P.(2002) Atypical antipsychotics. Canadian Journal of Psychiatry 47, 27-38.
307. Seeman, P., Corbett, R.&Van Tol, H.H.M.(1997) Atypical neuroleptics have low affi nity for dopamine D 2 receptors or are selective for D 4 receptors. Neuropsychopharmacology 16 , 93-110.
308. Seeman, P., Nam, D., Ulpian, C. et al. (2000) New dopamine receptor, D2 Longer, with unique TG splice site, in human brain. Molecular Brain Research 76, 132-141.
309. Seeman, P., Schwarz, J., Chen, J. F. et al. (2006) Psychosis pathways converge via D 2 High dopamine receptors. Synapse 60 , 319-346.
310. Seeman, P., Weinshenker, D., Quirion, R. et al. (2005) Dopamine supersensitivity correlates with D 2 High states, implying many paths to psychosis. Proceedings of the National Academy of Sciences USA 102, 3513-3518.
311. Semenova, S., Geyer, M.A., Sutcliffe, J.G. et al. (2008) Inactivation of the 5-HT(7) receptor partially blocks phencyclidine-induced disruption of prepulse inhibition. Biological Psychiatry 63 , 98-105.
312. Sergi, M.J., Rassovsky, Y., Widmark, C., et al. (2007) Social cognition in schizophrenia. Schizophrenia Research 90, 316-324.
313. Shapiro, D.A., Renck, S., Arrington, E. et al.(2003) Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28, 1400-1411.
314. Silvestri, S., Seeman, J.C., Negrte, S. et al. (1999) Dopamine D2 upregulation and 5HT2 downregulation measured after neuroleptic withdrawal using PET. Schizophrenia Research 36 , 247.
315. Soares, B.G., Fenton M.&Chue, P.(2000) Sulpiride for schizophrenia . Cochrane Database Systemtic Reviews , CD001162.
316. Sokoloff, P.(2005) Focus on clozapine: a new explanation for its atypical character. International Journal of Neuropsychopharmacology 8, 311-313.
317. Sokoloff, P., Martres, M.-P., Giros, B. et al. (1992) The third dopamine receptor (D 3) as a novel target for antipsychotics. Biochemical Pharmacology 43, 659-666.
318. Spooren, W., Riemer, C.&Meltzer, H.Y.(2005) NK3 receptor antagonists: the next generation of antipsychotics? Nature Reviews in Drug Discovery 4, 967-975.
319. Stephenson, C.M., Bigliani, V., Jones, H.M. et al. (2000) Striatal and extra-striatal D(2)/D(3) dopamine receptor occupancy by quetiapine in vivo. British Journal of Psychiatry 177, 408-415.
320. Stone, J.M., Morrison P.D.&Pilowsky, L.S.(2007) Glutamate and dopamine dysregulation in schizophrenia. Journal of Psychopharmacology 21, 440-452.
321. Stone, J.M., Bressan, R.A., Erlandsson, K. et al. (2005) Non - uniform blockade of intrastriatal D2/D3 receptors by risperidone and amisulpride. Psychopharmacology 180, 664-669.
322. Swainston-Harrison, T.&Scott, L. J.(2006) Ziprasidone. CNS Drugs 20, 1027-1052.
323. Szewczak, M.R., Corbett, R., Rush, D.K. et al.(1995) The pharmacological profi le of iloperidone, a novel atypical antipsychotic agent. Journal of Pharmacology and Experimental Therapeutics 274, 1404-1413.
324. Tadori, Y., Miwa, T., Tottori, K. et al. (2005) Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. European Journal of Pharmacology 515, 10-19.
325. Takano, A., Suhara, T., Yasuno, F. et al. (2006) The antipsychotic sultopride is overdosed. International Journal of Neuropsychopharmacology 9, 539-545.
326. Talvik, M., Nordstrom, A.L., Nyberg, S. et al.(2002) No support for regional selectivity in clozapine-treated patients: a PET study with [(11)C]raclopride and [(11)C]FLB 457. American Journal of Psychiatry 158, 926-930.
327. Tamminga, C.A.&Davis, J.M.(2007) The neuropharmacology of psychosis. Schizophrenia Bulletin 33, 937-946.
328. Tandon, R.&Nasrallah, H.A.(2006) Subjecting meta-analyses to closer scrutiny: Little support for differential effi cacy among second-generation antipsychotics at equivalent doses. Archives of General Psychiatry 63, 935-937.
329. Tandon, R., Keshaven, M.S.&Nasrallah, H.A.(2008) Schizophrenia, " Just the Facts ": What we know in 2008 Part 1: Overview. Schizophrenia Research 100, 4-19.
330. Tarazi, F.I.&Baldessarini, R.J.(1999) Dopamine D 4 receptors. Molecular Psychiatry 4, 529-538.
331. Tarsy, D.&Baldessarini, R.J.(2006) Epidemiology of tardive dyskinesia. Movement Disorders 21, 589-598.
332. Tauscher, J., Jones, C., Remington, G. et al. (2002) Signifi cant dissociation of brain and plasma kinetics with antipsychotics. Molecular Psychiatry 7, 317-321.
333. Tauscher, J., Hussain, T., Agid, O. et al. (2004) Equivalent occupancy of dopamine D1 and D2 receptors with clozapine. American Journal of Psychiatry 161, 1620-1625.
334. Tauscher-Wisniewski, S., Kapur, S., Tauscher, J. et al. (2002) Quetiapine: an effective antipsychotic in fi rst-episode schizophrenia despite only transiently high dopamine-2 receptor blockade. Journal of Clinical Psychiatry 63, 992-997.
335. Taylor, D.(2003) Ziprasidone in the management of schizophrenia . CNS Drugs 17, 423-430.
336. Tenback, D.E., van Harten, P.N., Slooff, C.J. et al. (2006) Evidence that early extrapyramidal symptoms predict later tardive dyskinesia . American Journal of Psychiatry 163, 1438-1440.
337. Tiihonen, J., Walhbeck, K., Lonnqvist, J. et al. (2006) Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after fi rst hospitalisation due to schizophrenia and schizoaffective disorder. British Medical Journal 333, 224.
338. Timmermann, D.B., Gronlien, J.H., Kohlhaas, K.L. et al. (2007) An allosteric modulator of the alpha7 nicotinic acetylcholine receptor possessing cognition-enhancing properties in vivo. Journal of Pharmacology and Experimental Therapeutics 323 , 294-307.
339. Travis, M.J., Busatto, G.F., Pilowsky, L.S. et al.(1997) Serotonin: 5-HT2A receptor occupancy in vivo and response to the new antipsychotics olanzapine and sertindole. British Journal of Psychiatry 171, 290-291.
340. Trichard, C., Paillere-Martinot, M.L., Attar-Levy, D, et al. (1998) Binding of antipsychotic drugs to cortical 5-HT 2A receptors. American Journal of Psychiatry 155, 505-508.
341. Truffi net, P., Tamminga, C.A., Fabre, L.F. et al. (1999) Placebo - controlled study of the D 4 /5-HT 2A antagonist fananserin in the treatment of schizophrenia. American Journal of Psychiatry 156 , 419-425.
342. Tuominen, H.J., Tiihonen J.&Wahlbeck, K.(2005) Glutamatergic drugs for schizophrenia. Schizophrenia Research 72, 225-234.
343. Turrone, P., Remington, G.&Nobrega, J.N.(2002) The vacuous chewing movement (VCM) model of tardive dyskinesia revisited. Is there a relationship to dopamine D 2 receptor occupancy? Neuroscience and Biobehavioral Reviews 26 , 361-380.
344. Turrone, P., Remington, G., Kapur, S. et al. (2005) Continuous but not intermittent olanzapine infusion induces vacuous chewing movements in rats. Biological Psychiatry 57, 406-411.
345. Uchida, H., Mamo, D.C., Kapur, S. et al. (2008) Monthly administration of long-acting injectable risperidone and striatal dopamine D 2 receptor occupancy. Journal of Clinical Psychiatry 69, 1281-1286.
346. Urbano, F.J., Leznik E.&Llinas, R.R.(2007) Modafi nil enhances thalamocortical activity by increasing neuronal electrotonic coupling. Proceedings of the National Acadamy of Sciences USA 104, 12554-12559.
347. Van Tol, H.H.M., Bunzow, J.R., Guan, H.-C. et al. (1991) Cloning of the gene for a human dopamine D 4 receptor with high affi nity for the antipsychotic clozapine. Nature 350, 610-614.
348. Vernaleken, I., Siessmeier, T., Buchholz, H.G. et al. (2004) High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. International Journal of Neuropsychopharmacology 7, 421-430.
349. Voruganti, L.,&Awad, A.G.(2004) Neuroleptic dysphoria. Psychopharmacology 171, 121-132.
350. Waddington, J.L., Scully, P.J.&O'Callaghan, E.(1997) The new antipsychotics, and their potential for early intervention in schizophrenia. Schizophrenia Research 28, 207-222.
351. Waddington, J.L., Kapur, S.&Remmington, G.J.(2003) The neuroscience and clinical psychopharmacology of fi rst-and second-generation antipsychotics drugs. In: Hirsh, S.R.&Weinbergery, D.R., eds. Schizophrenia . Oxford: Blackwell, pp. 421-441.
352. Waddington, J.L., Daly, S.A., McCauley, P.G. et al. (1994) Levels of functional interaction betweenD-1-like'and D-2-like'dopamine receptor systems. In: Niznik, H.B., eds. Dopamine Receptors . New York: Marcel Dekker, pp. 511-537.
353. Waddington, J.L.&Casey. D.E.(2000) Comparative pharmacology of classical and novel [second-generation] antipsychotics. In: Buckley, P.F.&Waddington, J.L., eds. Schizophrenia and Mood Disorders: The New Drug Therapies in Clinical Practice . Oxford: Butterworth Heinemann, pp. 3-13.
354. Waddington, J.L.&Morgan, M.G.(2001) Pathobiology of schizophrenia . In: Lieberman, J.A.&Murray, R.M., eds. Comprehensive Care of Schizophrenia: A Textbook of Clinical Management . London: Martin Dunitz, pp. 27-35.
355. Waddington, J.L.(1993) Pre-and postsynaptic D-1 to D-5 dopamine receptor mechanisms in relation to antipsychotic activity. In: Barnes, T.R.E., ed. Antipsychotic Drugs and their Side Effects . London: Academic Press, pp. 65-85.
356. Waddington, J.L.(2007) Neuroimaging and other neurobiological indices in schizophrenia. British Journal of Psychiatry 50 (Suppl.), s52-s57.
357. Waddington, J.L., Kingston, T.&O'Tuathaigh, C.M.P.(2007a) Longitudinal studies on course of illness in schizophrenia. A lifetime trajectory perspective. In: Carpenter, W.T.&Thaker , G., ed. The Year in Schizophrenia , Vol. 1. Oxford: Oxford Clinical Publishing, pp. 77-99.
358. Waddington, J.L., Corvin, A.P., Donohue, G. et al. (2007b) Functional genomics and schizophrenia. Endophenotypes and mutant models. Psychiatric Clinics of North America 30 , 365-399.
359. Waddington, J.L., O'Tuathaigh, C., O'Sullivan, G. et al. (2005) Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants. Psychopharmacology 181 , 611-638.
360. Wadenberg, M.L., Wiker, C.&Svensson, T.H.(2007) Enhanced effi cacy of both typical and atypical antipsychotic drugs by adjunctive alpha2 adrenoceptor blockade. International Journal of Neuropsychopharmacology 10, 191-202.
361. Wahlbeck, K., Cheine, M., Essali, A. et al. (1999) Evidence of clozapine's effectiveness in schizophrenia. American Journal of Psychiatry 156, 990-999.
362. Walterfang, M., Wood, S.J., Velakoulis, D. et al. (2006) Neuropathological, neurogenetic and neuroimaging evidence for white matter pathology in schizophrenia. Neuroscience&Biobehavioural Reviews 30, 918-948.
363. Wang, P.S., Schneeweiss, S., Avorn, J. et al(2005) Risk of death in elderly users of conventional vs. atypical antipsychotic medications. New England Journal of Medicine 353, 2335-2341.
364. Wijkstra, J., Lijmer, J., Balk, F.J. et al. (2006) Pharmacological treatment for unipolar psychotic depression. British Journal of Psychiatry 188, 410-415.
365. Wolkin, A., Barouche, F., Wolf, A.P. et al. (1989) Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. American Journal of Psychiatry 146 , 905-908.
366. Wong, A.H.&Van Tol, H.H.(2003) The dopamine D4 receptors and mechanisms of antipsychotic atypicality. Progress in Neuropsychopharmacology and Biological Psychiatry 27 , 1091-1099.
367. Wood, M.D., Scott, C., Clarke, K. et al.(2006) Aripiprazole and its human metabolite are partial agonists at the human dopamine D2 receptor, but the rodent metabolite displays antagonist properties. European Journal of Pharmacology 546 , 88-94.
368. Xiberas, X., Martinot, J.L., Mallet, L. et al. (2001) Extrastriatal and striatal D(2) dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. British Journal of Psychiatry 179, 503-508.
369. Yang, L.P.&Plosker, G.L.(2007) Paliperidone extended release. CNS Drugs 21, 417-425.
370. Yokoi, F., Grunder, G., Biziere, K. et al. (2002) Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597). Neuropsychopharmacology 27, 248-259.
371. Youngren, K.D., Inglis, F.M., Pivirotto, P.J. et al. (1999) Clozapine preferentially increases dopamine release in the Rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology 20, 403-412.
372. Zhang, L., Shirayama, Y., Iyo, M. et al. (2007) Minocycline attenuates hyperlocomotion and prepulse inhibition defi cits in mice after administration of the NMDA receptor antagonist dizocilpine . Neuropsychopharmacology 32, 2004-2010.